Literature DB >> 11889466

A new type of mutation causes a splicing defect in ATM.

Franco Pagani1, Emanuele Buratti, Cristiana Stuani, Regina Bendix, Thilo Dörk, Francisco E Baralle.   

Abstract

Disease-causing splicing mutations described in the literature primarily produce changes in splice sites and, to a lesser extent, variations in exon-regulatory sequences such as the enhancer elements. The gene ATM is mutated in individuals with ataxia-telangiectasia; we have identified the aberrant inclusion of a cryptic exon of 65 bp in one affected individual with a deletion of four nucleotides (GTAA) in intron 20. The deletion is located 12 bp downstream and 53 bp upstream from the 5' and 3' ends of the cryptic exon, respectively. Through analysis of the splicing defect using a hybrid minigene system, we identified a new intron-splicing processing element (ISPE) complementary to U1 snRNA, the RNA component of the U1 small nuclear ribonucleoprotein (snRNP). This element mediates accurate intron processing and interacts specifically with U1 snRNP particles. The 4-nt deletion completely abolished this interaction, causing activation of the cryptic exon. On the basis of this analysis, we describe a new type of U1 snRNP binding site in an intron that is essential for accurate intron removal. Deletion of this sequence is directly involved in the splicing processing defect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889466     DOI: 10.1038/ng858

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  68 in total

1.  Genome-wide detection of tissue-specific alternative splicing in the human transcriptome.

Authors:  Qiang Xu; Barmak Modrek; Christopher Lee
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

2.  Subdivision of large introns in Drosophila by recursive splicing at nonexonic elements.

Authors:  James M Burnette; Etsuko Miyamoto-Sato; Marc A Schaub; Jamie Conklin; A Javier Lopez
Journal:  Genetics       Date:  2005-03-31       Impact factor: 4.562

Review 3.  Splicing in action: assessing disease causing sequence changes.

Authors:  D Baralle; M Baralle
Journal:  J Med Genet       Date:  2005-10       Impact factor: 6.318

4.  An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon.

Authors:  Sushma-Nagaraja Grellscheid; Christopher W J Smith
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

5.  Identification of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons.

Authors:  Zhujun Zhang; Yasuaki Habara; Atsushi Nishiyama; Yoshinobu Oyazato; Mariko Yagi; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  J Hum Genet       Date:  2007-06-20       Impact factor: 3.172

6.  Deep Intronic Mutation in SERPING1 Caused Hereditary Angioedema Through Pseudoexon Activation.

Authors:  Pavla Hujová; Přemysl Souček; Lucie Grodecká; Hana Grombiříková; Barbora Ravčuková; Pavel Kuklínek; Roman Hakl; Jiří Litzman; Tomáš Freiberger
Journal:  J Clin Immunol       Date:  2020-01-25       Impact factor: 8.317

Review 7.  Splicing regulation: from a parts list of regulatory elements to an integrated splicing code.

Authors:  Zefeng Wang; Christopher B Burge
Journal:  RNA       Date:  2008-03-27       Impact factor: 4.942

8.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

Review 9.  A day in the life of the spliceosome.

Authors:  A Gregory Matera; Zefeng Wang
Journal:  Nat Rev Mol Cell Biol       Date:  2014-02       Impact factor: 94.444

10.  IL-7 receptor deficient SCID with a unique intronic mutation and post-transplant autoimmunity due to chronic GVHD.

Authors:  Manish J Butte; Charles Haines; Francisco A Bonilla; Jennifer Puck
Journal:  Clin Immunol       Date:  2007-09-12       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.